Background: Boric acid is a commonly cited treatment for recurrent and resistant yeast vaginitis, but data about the extent and mechanism of its antifungal activity are lacking.
Introduction
Candida vaginitis remains a common problem for women, and some individuals are bothered by repeated episodes of recurrent vaginal yeast infections or experience failure of conventional therapies. These problems can persist despite the availability of potent azole antifungal drugs that are used topically or orally. Because conventional therapies are not always successful, physicians and patients seek alternatives that might be effective in the face of therapeutic failure or that are less costly than commercial antifungal drugs. Among commonly mentioned alternatives is boric acid powder delivered intravaginally by means of a gelatin capsule or by a suppository. 1 -6 Ironically, this remedy is frequently mentioned by authors writing on the topic of yeast vaginitis, but little has been done to elucidate the extent, limitations or mechanism of boric acid's antifungal activity.
The use of boric acid as a home remedy has long been in existence, but a paper by Swate and Reed 7 purports to be the first study of the safety and efficacy of boric acid for vulvovaginitis treatment. Other clinical studies have followed, which focus on non-albicans vaginal candidiasis or Candida albicans vaginitis refractory to conventional antifungal pharmaceutical therapies. 8 -11 Generally, boric acid is considered to be a potential therapy for complicated infection, but not as a first-line treatment. It does have potential toxicity, especially if ingested or systemically absorbed. 12 Moreover, boric acid is contraindicated during pregnancy when it may produce anomalies, possibly due to inhibition of histone deacetylase. 13 While it is not the intention of this research to promote the clinical use of boric acid in lieu of potent antifungal drugs, including a number of over-the-counter drugs, the lack of information about its intrinsic antifungal properties, the availability of boric acid and the relatively low cost of the compound suggest to us that this study is a timely undertaking.
Methods
The 78 yeast isolates used in this study were C. albicans originally from clinical cases except for seven ATCC strains (including three C. albicans, two Candida glabrata and two Saccharomyces cerevisiae strains) and fluconazole-resistant strains, kindly provided by Dr Pfaller of the University of Iowa. Table 1 provides information about these strains, including susceptibility to fluconazole. All fungal isolates were stored long term at 2808C; prior to use, frozen stocks were recovered from storage by growth on Sabouraud dextrose agar (SDA). Overnight (308C) starter cultures were used to prepare inocula for individual experiments. Unless otherwise noted, experiments employed yeast nitrogen broth (YNB base with 0.5% glucose). Cultures were actively growing when diluted into experimental materials.
The chemicals used in this study were of analytical grade and were obtained from Fisher Scientific or Sigma-Aldrich Chemical Company.
Agar dilution was used for initial screening of the whole culture collection for antimicrobial activity, and broth dilution was employed for more precise MIC measurements. SDA plates were prepared to contain 100 000, 50 000, 40 000, 20 000, 10 000, 5000 and 2500 mg/L boric acid. At the highest concentration, boric acid was uniformly suspended in agar but precipitated upon cooling. Overnight starter cultures were diluted to contain between 1 Â 10 3 and 1 Â 10 4 cfu/mL and 10 mL was spotted onto each dilution, incubated at 378C for 24 h and evaluated for visible growth. MIC was the lowest concentration that prevented visible growth on the agar plates. A similar method was used to determine whether bacteria (also identified in Table 1) were inhibited by boric acid; however, nutrient agar with 0, 10 000 or 50 000 mg/L boric acid was used in lieu of SDA. Broth dilution testing was performed in microtitre format as described in the CLSI microdilution method, 14 but employed synthetic medium, 15 which is allowable in the CLSI method. As turbidimetric endpoints after 24 h of incubation at 378C, A 620 values were determined in a microplate reader (SLT Spectra, Tecan, Reading, UK). MICs are given as the drug concentration that leads to significant reduction (.50%) of growth. Viability in non-turbid wells was determined by plating a 10 mL aliquot on synthetic medium.
For growth studies under cold or anaerobic conditions, YNB was either equilibrated to 48C prior to inoculation or held in a GasPak w anaerobic system (BD Diagnostic Systems) overnight before inoculation and at the conclusion of the experiment, both turbidity and plate counts were used to monitor growth.
Metabolic activity was evaluated by inoculating 7 mL of Saboraud's Dextrose Broth (with or without boric acid) in screw top vials fitted with an inner vial containing 0.5 mL of fresh 1 M NaOH. Inocula consisted of 100 mL of test organisms (A 650 ¼ 1.0). The outer vials were sealed immediately after inoculation and incubated at 378C for 24 h. The CO 2 trapped by NaOH was titrated with 1:15 (v/v) concentrated HCl with Phenol Red as a pH indicator (visual transition range of pH 6.8-8.2).
Oxidative metabolism was also indicated by AlamarBlue w (Trek Diagnostic Systems, Cleveland, OH, USA) dye reduction, done by exposing selected yeast strains to 10 000 mg/L boric acid in YNB for 10, 20, 30 and 40 min at 378C. The controls consisted of each of the focus strains in YNB. At the conclusion of incubation, cultures were centrifuged and resuspended in YNB (to obviate any direct interaction of boric acid and the redox indicator) and 0.1 volumes of AlamarBlue w were added. Colour change from blue to pink was recorded as evidence of oxidative metabolism.
Vital staining employed propidium iodide (PI) as an indicator of physical disruption of cell integrity. Flow cytometry was used to quantify PI vital staining. The technique involved mixing aliquots of boric acid-treated cultures with Vindolov's PI at room temperature for 10 min followed by dilution in 500 mL of PBS. Flow cytometry employed the FacScan instrument (BD Biosciences) set for linear amplification of forward and side scatter channels and logarithmic amplification of the Fl2-h channel. The cultures not treated with boric acid were adjusted so that .95% were below 1 Â 10 1 on the Fl2-h scale, and 10 000 events were counted. Test organisms were also exposed to 658C for 15 min as a positive (cell damage) control.
Flow cytometry was also used to evaluate the activity of the CDR1 efflux pump. This assay has been described elsewhere 16 and employs a recombinant C. albicans strain. This organism has one CDR1 allele replaced with green fluorescent protein (GFP), which allows tracking of up-regulation of CDR1 by measuring GFP fluorescence in the Fl1-h channel of the FacScan instrument.
Ergosterol estimation was based on the work of Arthington-Skaggs et al. 17 Cultures were prepared in 100 mL volumes of YNB with or without 1000 mg/L boric acid. After 48 h at 378C in a shaking water bath (150 rpm), cells were harvested by centrifugation, washed with sterile water and the wet weight of each culture determined in order to normalize data for differences in growth yield. Wet pellets were digested at 858C for 1 h in 25% KOH (w/v) in 35% (v/v) absolute ethanol. After digestion, water and heptane were added and mixed vigorously. The absorbances of the heptane extracts were measured at the ergosterol absorbance maxima (262, 272, 282 and 294 nm) and normalized to pellet weights.
Biofilm production was studied as in previous reports 18 by allowing overnight growth of C. albicans to adhere to flat-bottomed styrene microtitre plates for 1 h at 378C. Non-adhered cells were the removed by repeated washes. Biofilm was stimulated by adding YNB medium containing 5 mg/mL sodium choleate. After 24 h at 378C, the wells were washed and re-fed with YNB with or without boric acid. Biofilm was allowed to develop for an additional 24 h after which the wells were mildly washed and stained with safranin. After a second wash, denatured alcohol was added to the wells and colour was read spectrophotometrically at 540 nm in a microplate reader.
Hyphal transformation was monitored microscopically. Test organisms were placed in human serum-containing media (10% v/v) with or without boric acid (10 000 or 50 000 mg/L), incubated at 378C and aliquots removed at intervals for confirmation of the presence of germ tubes, pseudohyphae and hyphae. Two strains (986 and 142) were used. Photo documentation of the results was made at Â400 magnification on a Zeiss Axiophot system (Zeiss, Oberkochen, Germany).
Results
The agar dilution assay was used as a preliminary screen for the collection of clinical and laboratory isolates listed in Table 1 . Although a typical intravaginal dose of boric acid might be .100 000 mg/L boric acid (assuming a total volume of vaginal fluid of 3 mL), this concentration in growth medium formed crystalline precipitates when cooled to room temperature. On this medium, none of the isolates formed visible growth. As noted in Table 2 , all strains were unable to form visible growth on 50 000 mg/L boric acid. Table 2 also shows that $85% of fluconazole-susceptible strains were inhibited by 5000 mg/L boric acid, whereas 20 000 mg/L was needed to inhibit 90% of fluconazole-resistant strains. But 2500 mg/L boric acid inhibited $50% of fluconazole-susceptible strains and 5000 mg/L inhibited half of the fluconazole-resistant strains. The proportion of fluconazole-susceptible clinical isolates (87%) susceptible to 40 000 mg/L boric acid was not different from the proportion (80%) of resistant strains (P ¼ 0.5012 by Fisher's exact test) inhibited at the same boric acid concentration. As Table 3 shows, boric acid was also inhibitory to prokaryotic organisms.
To obtain a more precise estimate of the MIC of boric acid, broth microdilution testing was performed (Table 4) . For all yeast strains tested, 96.2% were inhibited by 3125 mg/L and 39.7% of strains were inhibited by 1563 mg/L; all fluconazoleresistant isolates were inhibited by 3125 mg/L boric acid, but susceptibility dropped precipitously to 2% of strains at 1563 mg/L. By plating 10 mL from each well on SDA, we showed that in all cases yeast remained alive, even at concentrations of 25 000 mg/L boric acid. This indicates that boric acid in the tested concentration range is fungistatic rather than fungicidal.
Six 'focus strains', representing clinical C. albicans isolates with MICs of fluconazole ranging from 0.5 to .32 mg/L and MICs of boric acid of 1562 and 3125 mg/L, were selected for an examination of the fungistatic effect of boric acid. These organisms were incubated with synthetic medium (YNB) containing 0, 10 000 and 50 000 mg/L boric acid. Viable counts obtained during the first 5 h of incubation at 378C showed little difference between these samples. However, by 24 h, the control showed significant growth while boric acid-treated cultures declined as shown in Table 5 . At 24 h, no colonies developed from any of the strains exposed to 50 000 mg/L boric acid, indicating a time-and dose-dependent slow fungicidal effect.
To determine whether metabolic activity of yeast was required for boric acid inhibition, culture of the six focus organisms was done at 378C and compared with growth at 48C. Plate counts showed that the lower temperature was protective for cells exposed to both 10 000 and 50 000 mg/L boric acid, though some slight inhibition still occurred in medium with 50 000 mg/L boric acid (data not shown). Some authors have opined that boric acid is inhibitory because it is a weak acid. To illuminate this concept, YNB with each of six organic acids or sodium borate at 0.164 M (equivalent to the molarity of 10 000 mg/L boric acid) was inoculated with the focus organisms. The pH of these media was measured prior to inoculation and growth was determined after 24 h at 378C. As can be read from Figure 1 , the pH of the boric acid medium was 5.118 and cell counts after 24 h of incubation were $1 log less than those in the YNB control medium ( pH 5.483). Other acids in YNB ranged in pH from 1.983 for maleic acid to 3.658 for acetic acid. In these media, cell counts after 24 h of incubation were only 0.2 log less than those in YNB. With the exception of maleic or fumaric acids ( pH , 3), organic acids yielded plate counts comparable to the YNB control. The medium containing sodium borate ( pH 9.027) yielded cells counts lower than the medium containing boric acid.
To determine whether boric acid generated biological toxicity through reactive oxygen species, boric acid inhibition was compared under aerobic and anaerobic conditions. As shown in Figure 2 , exclusion of oxygen had a protective effect.
Anaerobic growth yield was diminished $1 log under reducing conditions compared with aerobic growth. The highest boric acid concentration decreased counts in aerobic culture by 2.58 logs, whereas in anaerobic culture the decrement due to 50 000 mg/L boric acid was only 1.9 logs. Similarly, at 10 000 mg/L boric acid counts were diminished by 2.29 logs aerobically and by 1.26 logs anaerobically.
Quantitative evidence of cell damage to boric acid-treated yeast was obtained with PI staining detected by flow cytometry. PI staining of boric acid-treated cells of strain 142 was done at 17, 24 and 48 h. Figure 3 shows that 97% of control cells (24 h of incubation in YNB at 378C) were nonfluorescent and mean channel fluorescence for control cells was 14.58. Heat-damaged cells, in contrast, showed 99.83% of cells having greater than baseline fluorescence. Boric acidtreated cells showed a minimal uptake of PI at 10 000 mg/L (3.95% fluorescent cells, mean channel fluorescence 10.11). Cells exposed to 50 000 mg/L boric acid showed some intrusion of PI; 45.51% of cells showed Fl2-h fluorescence greater than baseline and mean channel fluorescence was 49.51. As incubation continued up to 48 h, a progressive increase in PI staining at both 10 000 and 50 000 mg/L boric acid occurred and the lower concentration of boric acid showed substantial staining by 48 h as well.
To determine whether boric acid perturbed ergosterol synthesis, extraction and estimation of membrane sterols were performed on cultures with a relatively low (1000 mg/L) concentration of boric acid. The low concentration of boric acid was used to permit the development of sufficient biomass for analysis. Even at this relatively low boric acid concentration, the average amount of biomass generated was decreased to 0.28 + 0.105 g wet weight/100 mL of culture compared with control cultures in YNB that yielded an average of 0.376 + 0.038 g wet weight/100 mL of culture. Figure 4 (a) compares the scans obtained from a control and the corresponding boric acid-exposed culture (normalized for biomass). As shown in Figure 4 (b), boric acid reduced ergosterol concentrations in five of the six focus strains. Boric acid decreased ergosterol content by an average of 21%, and paired comparisons by t-test showed that the decrement in relative ergosterol content was significant (P ¼ 3 Â 10 25 ). Evaluation of CO 2 generation in the presence of boric acid was performed by trapping CO 2 with NaOH inside closed vessels. The average amount (+SD) of H þ required to titrate the residual NaOH in the YNB control was 1.53 mM (+0.044) while 10 000 and 50 000 mg/L boric acid required 2.025 + 0.305 and 2.330 + 0.289, respectively. Both were significantly greater (less CO 2 production) than the YNB controls (P ¼ 0.03 
-test).
To more sensitively detect an effect on oxidative metabolism, focus strains were exposed to 10 000 mg/L boric acid and stained with AlamarBlue w . Within 45 min, controls showed visual evidence of reduction of AlamarBlue w as they developed a pink colour, whereas all six boric acid-exposed strains showed no change in colour until $2 h after addition of the dye. This indicates that the metabolic inhibition related to boric acid occurred quickly but the cells remained alive and the metabolic inhibition was reversible.
We then sought to determine whether the restriction of fungal growth and metabolic processes influences the expression of virulence factors. Biofilm formation is increasingly being recognized as a contributor to mucosal infections. 19 In our experiment, biofilm formation was induced by sodium choleate (M. E. and B. L., unpublished observation). As Figure 5 shows, boric acid reduced biofilm formation by 40%. After 48 h of incubation with the inducer, boric acid-exposed cells had increased the biofilm mass by a factor of only 1.3 (fifth bar), whereas boric acid-free controls increased the biofilm mass by a factor of 2.1 (fourth bar). Hyphal growth is also considered to be part of the virulence mechanism of C. albicans. After 5 h of exposure to 10% serum, approximately half of the control cells had developed germ tubes, whereas the same yeast strain in 10 000 and 50 000 mg/L boric acid showed no evidence of germination. At 9 h, the germinated forms in serum had become elongated and many looked like true hyphae. Figure 6 shows the difference between cells in serum with and without boric acid after 18 h. It was notable that in addition to boric acid preventing germination, it clearly held the number of yeast at low levels. To determine whether boric acid affected the drug efflux pump CDR1, a recombinant Candida reporter strain (CaSA1) 16 was incubated with boric acid and assayed for CDR1 expression. After 1-5 h of exposure of CaSA1 to 10 000 or 50 000 mg/L boric acid, the signal from boric acid-treated yeast was almost completely eliminated compared with controls. This suggests that CDR1 was not up-regulated in boric acid-treated cells and even basal levels appeared to be suppressed (data not shown).
Discussion
Little is known about the mechanism of antifungal effects of boric acid, which is used clinically for the treatment of yeast vaginitis after treatment with conventional drugs has failed. 1 -6 Clinical reports indicate success in treating vaginal candidiasis, especially non-albicans vaginitis, 7 -11 with boric acid. The literature is relatively silent on the presumed reasons for its efficacy, a fact that is especially ironic in view of the frequent recitation of its utility in standard texts.
This report confirms that boric acid inhibits C. albicans in vitro, but the effect is fungistatic with high concentrations near the limit of solubility over prolonged incubation being required to cause a loss of viability. Initial observations were based on agar dilution, but when 100 000 mg of boric acid per litre of boiling agar medium cooled, the boric acid began to precipitate, which is not surprising considering the solubility of boric acid (20 000 mg/L). 20 A volume of at least 9 mL would be required to dissolve 600 mg of boric acid in water, and solvents such as vaginal fluid or SDA containing a high concentration of solutes would probably dissolve less boric acid than water. 1 Thus, a 600 mg dose would not be likely to completely dissolve intravaginally, but might serve as a depot, being solubilized over time. A study by Venkataraman et al. 21 found that healthy volunteers wearing an internal collection device produced between 0.2 and 1 mL of vaginal fluid during a 30 min collection. A study by Kale et al. 22 suggested that the vaginal fluid pool was no more than 5 mL. It should be noted that pharmacokinetic studies have not been done to determine the concentration and time course of 600 mg of boric acid powder in the vagina; in addition, the distribution over the surface of the tissue has not been determined.
While agar dilution showed that .90% of Candida strains were prevented from growing on 10 000 mg/L boric acid, broth dilution indicated that .90% of strains were inhibited by 3100 mg/L boric acid. This difference may relate to less mobilization of the poorly soluble boric acid from the solid medium. In considering activity in vivo, it is important to realize that boric acid is fungistatic, though at high concentrations and with prolonged exposure, yeast numbers in culture diminished to undetectable levels. Vital staining confirmed that cell integrity was increasingly compromised over time. Plate count viability decreased more rapidly than increases in vital staining. Clearly, boric acid is not intrinsically as potent as many antifungal pharmaceuticals, but may nevertheless derive clinical effect from high doses and the continued release from vaginal depots of incompletely dissolved drugs, which are replenished daily for 14 days in typical use.
Bacteria were not a focal point of this study, but a variety of species were inhibited by this compound in the same range of concentrations that prevented turbidity of Candida in broth cultures. While we did not challenge bacterial species typical of the vaginal flora, the broad range of bacteria inhibited by boric acid implies that potentially harmful and beneficial vaginal organisms may be inhibited when intravaginal boric acid therapy is undertaken. Miers and Chow 23 also noted that uropathogens were inhibited by boric acid in a range similar to that reported in this study. Future clinical studies of boric acid treatment should evaluate the effects on vaginal flora-good and bad. The finding that boric acid affects bacteria indicates that the antimicrobial effect is not limited to the eukaryotic life forms, though it does not mean that the antimicrobial targets are the same in eukaryotic and prokaryotic organisms. Potential targets shared by prokaryotes and eukaryotic organisms include cell membranes, metabolic pathways and enzymes driving those pathways and DNA integrity or replication and gene expression. Microarray techniques for probing the transcriptome after boric acid exposure would be the most comprehensive approach to identifying specific targets in yeast, but in the absence of this technology, we applied several informative phenomenological evaluations.
In the absence of direct investigations, some authors have suggested that boric acid inhibits yeast because it is a weak acid.
However, other organic acids, some of which have significantly lower pK a s than boric acid did not prove inhibitory to Candida. It was also observed that sodium borate is intrinsically more inhibitory than boric acid and it provided an alkaline pH in culture medium, suggesting that boron may be a more important factor in fungal inhibition than pH alone. This is especially likely because mole for mole, sodium borate has three times the boron that boric acid does.
The fact that vital staining showed slow compromise of cell integrity means that sudden physical membrane damage appears not to be the primary cause of the antifungal effect of boric acid. This finding is consistent with the fungistatic as opposed to the fungicidal nature of boric acid. However, we could also show that low concentrations of boric acid reduce the relative ergosterol content of yeast membranes. Membranes having diminished ergosterol content might be more susceptible to hostile host defence factors that in turn may lead to accumulating damage and is consistent with clinical efficacy despite a slow loss of viability. This is consistent with the modest effect that a high concentration of boric acid had on cell integrity as determined by PI staining (,50% staining after 24 h of incubation with 50 000 mg/L boric acid). In considering the clinical applicability of this research, yeast with reduced membrane ergosterol would be expected to have altered susceptibility to azole-type antifungals, and while boric acid is considered by clinicians as an alternative to azole therapy, it may be of value to explore boric acid to synergize the therapeutic effect of azoles.
The decrement in ergosterol could be explained if boric acid produced some limiting effect on one or more metabolic pathways. It is known that a key step in ergosterol biosynthesis requires a demethylation of lanosterol at the 14 position by a cytochrome p450 and an enzyme linked to cellular oxidative metabolism. This study demonstrated that CO 2 production was significantly limited by boric acid and, in a separate experiment, . This suggests that rapid interaction with cellular targets occurs even while the drug acts fungistatically. The metabolic explanation gains support from the finding that incubation at near freezing temperatures appeared to protect yeast from boric acid-induced damage. Likewise, the study conducted under anaerobic conditions also suggests that aerobic metabolism may play a role in boric acid toxicity.
Because limited information is available on biological activities of boron, clues may be gained from the better known actions of the semi-metal arsenic, a near neighbour in the periodic table. Arsenicals derive toxicity from the perturbation of mitochondrial function, disruption of oxidative phosphorylation and the generation of free radicals directly 24 and indirectly through the mobilization of iron away from ferritin, which generates reactive oxygen species. 25 The metabolism-related observations made in the present study are consistent with similarity in some of the effects of arsenate and borate.
The finding that even high concentrations of boric acid require an extended time period to substantially diminish yeast viability raises additional questions about the possibility that yeast may adapt to boric acid exposure. Efflux pumps are features of microorganisms that allow them to evade the harmful effects of potentially inimical substances. This study did not implicate CDR1 in the protection of the yeast from boric acid growth inhibition. In fact, boric acid was very effective in shutting down CDR1 expression, a finding that fulfils one of our long-term goals, namely to find a drug or reagent that can render yeast more susceptible to antifungal drugs through inhibition of CDR1p.
Future investigations should consider other enzyme systems or transporters as potential targets of boric acid. BOR1 in Saccharomyces moves borate, arsenate and bicarbonate across the cell membrane, 26 and we have noted from bioinformatic searches of the Candida genome the possible presence of a homologue of BOR1 in C. albicans. This will be an important topic in follow-up studies engendered by this initial investigation of boric acid action on yeast cell physiology.
While boric acid may cause some damage due to the generation of oxygen free radicals as suggested by a protective effect of anaerobic exposure to boric acid, it remains an open question of whether the boron itself or some reaction product of the boric acid causes disruptions leading to inhibition of microorganisms. The possibility that toxic chemical compounds based on boron chemistry might develop intracellularly is suggested by the existence of a unique boron-containing antibiotic-boromycin, a naturally occurring substance isolated from Streptomyces. 27 Limited information on this boroncoordinated polyether is available in the literature, but the action of this compound is believed to be due to damage to the cytoplasmic membrane, which also seems to occur over time in boric acid-treated yeast.
Given our findings that boric acid is limited in its intrinsic antifungal potency, it may be more important to highlight the effects of boric acid on hyphal transformation and biofilm development. Theoretically, arrest of fungal growth coupled with inhibition of virulence attributes could result in biological activity greater than that predicted from in vitro measures of MIC. We obtained evidence that even relatively low concentrations of boric acid interfered with some factors that contribute to Candida virulence. As with any anti-infective that is not microbicidal, the usefulness of the therapeutic probably relies on host defence factors to restore the healthy balance in the vaginal microenvironment. However, a full understanding of how boric acid functions in vivo will require studies that go beyond this in vitro work.
We have provided an initial look at a compound that is widely used, may have local toxicities that are incompletely appreciated and has a mechanism of action that is poorly understood. It is surprising that so little is known about a compound that is so commonly used. Follow-on studies should provide physicians who have an interest in using this remedy with a more rational basis for their clinical decisions.
